Slide 1: Investor Conference Call 9M 2024 Results
Investor Conference Call 9M 2024 Results Joachim Kreuzburg, Florian Funck, René Fáber Sartorius | Sartorius Stedim Biotech | October 17, 2024 1
Slide 2: 9-month 2024: Results in line with expectations
Sartorius Group 9-month 2024: Results in line with expectations ▪ 9M sales revenue close to prior-year level; significant increase in order intake ▪ Recurring business: revenue in both divisions growing lsd, positive dynamics over the year ▪ BPS division: 9M revenue almost on prior-year level; soft
Slide 3: Agenda
Agenda Sartorius Group 9 M 2024 results | FY 2024 guidance Sartorius Stedim Biotech Group 9 M 2024 results | FY 2024 guidance Questions & Answers 3
Slide 4: Business gradually normalizing after four years of unprecedented volatility
Sartorius Group Business gradually normalizing after four years of unprecedented volatility Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2019 2020 2021 2022 2023 2024 Sales revenue ex Covid Covid-19 related sales Order intake 4
Slide 5: Sales revenue close to prior-year level; robust profitability
Sartorius Group Sales revenue close to prior-year level; robust profitability Sartorius Group 9 M 2023 9 M 2024 in % in % cc 1 in millions of € unless otherwise specified Sales revenue 2,546 2,474 -2.8 -2.0 Order intake 2,201 2,326 +5.7 +6.6 Underlying EBITDA2 733 686 -6.4 Underlying EBITDA2 margin
Slide 6: Growth in EMEA; high comps in Americas; China weighs on Asia|Pacific
Sartorius Group Growth in EMEA; high comps in Americas; China weighs on Asia|Pacific EMEA Americas Asia | Pacific Sales by region Sales | € in millions Sales | € in millions Sales | € in millions in % +5.0% -9.1% -1.6% EMEA Americas 1,020 ~41% ~36% 973 973 879 600 574 €2,474m Asia | Pacific 9M 2023
Slide 7: Bioprocess Solutions: Revenues close to PY, order intake significantly up
Sartorius Group Bioprocess Solutions: Revenues close to PY, order intake significantly up Order intake Sales revenue Underlying EBITDA & margin € in millions € in millions € in millions +8.4% cc -0.8% cc +7.5% -1.5% -4.0% 1,993 1,962 1,708 1,836 592 568 55 600 400 50 500 45 300 400 40 300 200 29.7 2
Slide 8: Lab Products & Services: End markets remain soft
Sartorius Group Lab Products & Services: End markets remain soft Order intake Sales revenue Underlying EBITDA & margin € in millions € in millions € in millions -6.5% cc +0.3% cc -7.5% -0.8% -16.3% 493 553 511 141 490 118 25.6 23.2 9M 2023 9M 2024 9M 2023 9M 2024 9M 2023 9M 2024 ▪ Instrument busines
Slide 9: Increasing cashflow; capex decreases as planned
Sartorius Group Increasing cashflow; capex decreases as planned Sartorius Group 9M 2023 9M 2024 in % in millions of € unless otherwise specified ▪ Extraordinary items in 2024 driven mainly by reorganization measures and corporate projects Underlying EBITDA 733 686 -6.4 ▪ Financial result 2024 impact
Slide 10: Deleveraging progresses as expected; committed to investment-grade rating
Sartorius Group Deleveraging progresses as expected; committed to investment-grade rating Key financial indicators Net debt and net debt to underlying EBITDA Sartorius Group Dec. 3 1 , Sept. 30, in millions of € unless otherwise specified 2023 2024 6.0 5,000 5.0 Non-current assets 7,7891 7,825 4,000
Slide 11: Guidance 2024 confirmed
Sartorius Group Guidance 2024 confirmed Guidance 20241 Sales revenue growth Underlying EBITDA margin Sartorius Group on prior-year level with bandwidth of +/- lsd % growth 27% - 29% Bioprocess Solutions on prior-year level with bandwidth of +/- lsd % growth 28% - 30% on prior-year level Lab Products
Slide 12: Agenda
Agenda Sartorius Group 9M 2024 results | FY 2024 guidance Sartorius Stedim Biotech Group 9M 2024 results | FY 2024 guidance Questions & Answers 12
Slide 13: Business gradually normalizing after four years of unprecedented volatility
Sartorius Stedim Biotech Group Business gradually normalizing after four years of unprecedented volatility Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2019 2020 2021 2022 2023 2024 Sales revenue ex Covid Covid-19 related sales Order intake 13
Slide 14: Sales revenue slightly down; order intake significantly up, robust profitability
Sartorius Stedim Biotech Group Sales revenue slightly down; order intake significantly up, robust profitability Sartorius Stedim Biotech Group 9M 2023 9M 2024 in % in % cc1 in millions of € unless otherwise specified Sales revenue 2,069 2,029 -1.9 -1.3 Order intake 1,760 1,895 +7.7 +8.5 Underlying E
Slide 15: Growth in EMEA and Asia|Pacific; high comps in Americas
Sartorius Stedim Biotech Group Growth in EMEA and Asia|Pacific; high comps in Americas EMEA Americas Asia|Pacific Sales by region Sales | € in millions in % Sales | € in millions Sales | € in millions +5.9% -9.7% +1.3% EMEA Americas 850 ~ 42% ~ 35% 804 799 466 719 460 €2,029m 9M 2023 9M 2024 Asia|Pa
Slide 16: Increasing cashflow; capex decreases as planned
Sartorius Stedim Biotech Group Increasing cashflow; capex decreases as planned Sartorius Stedim Biotech Group 9M 2023 9M 2024 in % in millions of € unless otherwise specified Underlying EBITDA 594 565 -4.9 ▪ Extraordinary items in 2024 driven mainly by Extraordinary items 76 58 -23.5 reorganization
Slide 17: Deleveraging progresses as expected
Sartorius Stedim Biotech Group Deleveraging progresses as expected Key financial indicators Net debt and net debt to underlying EBITDA Sartorius Stedim Biotech Dec. 31, Sept. 30, 4,000 6.0 Group 2023 2024 5.0 in millions of € unless otherwise specified 3,000 4.0 Non-current assets 6,3151 6,377 2,000
Slide 18: Guidance 2024 confirmed
Sartorius Stedim Biotech Group Guidance 2024 confirmed Guidance 20241 Sales revenue growth Underlying EBITDA margin on prior-year level Sartorius Stedim Biotech Group 27% - 29% with bandwidth of +/- lsd % growth ▪ Net debt to underlying EBITDA anticipated to be 2.5 to 3.0 at year-end ▪ Capex ratio e
Slide 19: Questions & Answers
19 Questions & Answers EARTORILS
Slide 20: Disclaimer
Disclaimer This presentation contains statements concerning the future performance of the Sartorius and the Sartorius Stedim Biotech Groups. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee tha